Critical care therapeutics in major developed market size, share, growth, trend & forecast to 2020

Critical Care Therapeutics in Major Developed Market Size, Share, Growth, Trend & Forecast to 2020: Radiant Insights, Inc Summary GBI Research, the leading business intelligence provider, has released its latest research: "Critical Care Therapeutics in Major Developed Markets to 2020 - New and Late-Stage Four-Factor PCCs and Recombinant Products to Drive Market", which provides in-depth analysis of the critical care market in the US, UK, France, Germany, Italy, Spain, Japan and Canada. The report provides an estimation of market size for 2013, along with market forecasts to 2020. It covers critical care indications that are being treated using the five major plasma-derived products of albumin, anti-thrombin concentrates, factor XIII concentrates, fibrinogen concentrates, and prothrombin complex concentrates.

Browse Full Report With TOC @ http://www.radiantinsights.com/research/critical-caretherapeutics-in-major-developed-markets-to-2020-new-and-late-stage-four-factor-pccs-andrecombinant-products-to-drive-market The total value of the critical care market in the major developed markets was estimated at $1.8 billion in 2013 and is expected to grow at a Compound Annual Growth Rate (CAGR) of 4.7% to $2.5 billion in 2019. This growth is attributed to the recent approval of new factor concentrates in the US that are expected to witness increasing uptake in the forecast period. Factor concentrates are increasingly preferred due to their lower infection risks over older alternatives such as FFP and cryoprecipitate in critical care settings.

The US accounts for the largest share (41%) of the global critical care market and is expected to post high growth at a CAGR of 7.5% until 2020. KCentra, the first four-factor PCC in the US, and Tretten, the first recombinant FXIII concentrate, were approved in 2013 and are expected to witness good uptake in the forecast period. Two additional factor concentrates approved in the US in 2009 - RiaStap (human fibrinogen concentrate) and ATryn (recombinant AT concentrate) - are also expected to increase their uptake, which will contribute to market growth. With no new significant launches in the forecast period, the European market is estimated to witness much slower growth, with the UK at a CAGR of 3.0%, France at 2.5%, Germany and Spain both at 2.3%, and Italy at 2.0% Scope The report analyzes treatment usage patterns, market characterization, pipeline analysis and key licensing and co-development deals in critical care in the eight major developed markets of the US, UK, France, Germany, Italy, Spain, Japan and Canada.The report includes - A brief introduction to the five major plasma-derived products in critical care and the indications that they are being used to treat, as well as disease overview, epidemiology, other treatment options, and treatment patterns - Analysis of major marketed products in critical care, covering product performance in terms of the safety and efficacy of recent approvals

- A review of the critical care pipeline, including individual analysis of promising late-stage pipeline drugs that are most likely to enter the market during the forecast period - Multi-scenario forecasts of the critical care market over the 2013-2020 period in the eight major developed markets - Key drivers and restraints that have had and are expected to have a significant impact on the market - An overview of major licensing and co-development agreements that could affect growth trends Browse Full Report With TOC @ http://www.radiantinsights.com/research/critical-caretherapeutics-in-major-developed-markets-to-2020-new-and-late-stage-four-factor-pccs-andrecombinant-products-to-drive-market Reasons to buy The report will enhance your decision-making capability by allowing you to - Align your product portfolio to markets with high growth potential - Develop market entry and expansion strategies by identifying the regions and therapeutic segments poised for strong growth - Devise effective, tailored strategies for each country through the understanding of key drivers and barriers in the critical care drugs market - Develop key strategic initiatives based on an understanding of key focus areas and leading companies - Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships Table of Contents Table of Contents 5 1.1 List of Tables 7 1.2 List of Figures 8 2 Introduction 9 2.1 Albumin in Critical Care 9 2.1.1 Overview 9 2.1.2 Diseases or Conditions Indicated for Albumin 9 2.1.3 Epidemiology 10 2.1.4 Other Treatment Options 10

2.1.5 Treatment Patterns 10 2.2 Anti-Thrombin III Concentrates in Critical Care 11 2.2.1 Overview 11 2.2.2 Anti-Thrombin Deficiencies 11 2.2.3 Epidemiology 11 2.2.4 Treatment Options 12 2.2.5 Treatment Patterns 12 2.3 Factor XIII Concentrates in Critical Care 12 2.3.1 Overview 12 Browse Full Report With TOC @ http://www.radiantinsights.com/research/critical-caretherapeutics-in-major-developed-markets-to-2020-new-and-late-stage-four-factor-pccs-andrecombinant-products-to-drive-market 2.3.2 FXIII Deficiencies 13 2.3.3 Epidemiology 13 2.3.4 Treatment Options 13 2.3.5 Treatment Patterns 13 2.4 Fibrinogen Concentrates in Critical Care 14 2.4.1 Overview 14 2.4.2 Fibrinogen Deficiencies 14 2.4.3 Epidemiology 15 2.4.4 Treatment Options 15 2.4.5 Treatment Patterns 15 2.5 Prothrombin Complex Concentrate in Critical Care 16 2.5.1 Overview 16 2.5.2 Diseases or Conditions Indicated for Prothrombin Complex Concentrate 16 2.5.3 Epidemiology 17 2.5.4 Treatment Options 17

2.5.5 Treatment Patterns 18 3 Therapeutic Landscape 19 3.1 Albumin Products 19 3.1.1 Buminate (albumin, human) - Baxter 19 3.1.2 Zenalb (human albumin) - Bio Products Laboratory 19 3.1.3 Human Albumin Biotest (albumin, human) - Biotest 19 3.1.4 AlbuRx (albumin) - CSL Behring 19 3.1.5 Albuminar (albumin, human) 5% - CSL Behring 20 3.1.6 Albutein (albumin (human)) - Grifols 20 3.1.7 Albuked (human albumin) - Kedrion 20 Browse Full Report With TOC @ http://www.radiantinsights.com/research/critical-caretherapeutics-in-major-developed-markets-to-2020-new-and-late-stage-four-factor-pccs-andrecombinant-products-to-drive-market 3.1.8 Vialebex (human albumin) - French Fractionation and Biotechnology Laboratory 21 3.1.9 Albunorm (human albumin) - Octapharma 21 3.1.10 Alburaas (human albumin) - Shanghai RAAS 21 3.2 Anti-Thrombin Concentrates 21 3.2.1 Atryn (antithrombin alfa) - rEVO Biologics 21 3.2.2 Thrombate III (AT III human) - Grifols 23 3.2.3 Anbinex (AT III human) - Grifols 23 3.2.4 Kybernin P (AT III human) - CSL Behring 23 3.2.5 Aclotine (AT III, human) - French Fractionation and Biotechnology Laboratory 24 3.2.6 Anti-Thrombin III (AT III human) - Baxter 24 3.2.7 AT III Kedrion (AT III human) - Kedrion 24 3.2.8 Neuart (AT III, human) - Mitsubishi Tanabe 24 3.3 Factor XIII Concentrates 25 3.3.1 Fibrogammin/Corifact (factor XIII) - CSL Behring 25

3.3.2 NovoThirteen/Tretten (catridecacog) - Novo Nordisk 25 3.4 Fibrinogen Concentrates 26 3.4.1 Haemocomplettan P/Riastap (fibrinogen concentrate, human) - CSL Behring 26 3.4.2 Clottafact/Clottagen (fibrinogen concentrate, human) - French Fractionation and Biotechnology Laboratory 27 3.4.3 Other Marketed Fibrinogen Concentrates 27 3.5 Prothrombin Complex Concentrates 27 3.5.1 Beriplex P/N/Confidex/Kcentra (Prothrombin Complex Concentrate [Human]) - CSL Behring 27 3.5.2 Bebulin VH (factor IX complex, vapor heated) - Baxter 27 3.5.3 Cofact (prothrombin complex concentrate) - Sanquin 28 3.5.4 Octaplex 500 (human prothrombin complex) - Octapharma 28 3.5.5 Profilnine SD - Grifols 28 3.5.6 Uman Complex DI - Kedrion 28 Browse Full Report With TOC @ http://www.radiantinsights.com/research/critical-caretherapeutics-in-major-developed-markets-to-2020-new-and-late-stage-four-factor-pccs-andrecombinant-products-to-drive-market 4 Pipeline for Critical Care Market 29 4.1 Overview of Pipeline 29 4.2 Promising Pipeline Candidates 30 4.2.1 Octaplex 500 (human prothrombin complex) - Octapharma 30 4.2.2 KW-3357- Kyowa Hakko Kirin 30 4.2.3 Human AT Concentrate - Grifols 30 5 Critical Care Market Forecast to 2020 31 5.1 Geographical Markets 31 5.1.1 Major Developed Markets 31 5.1.2 US 34 5.1.3 Top Five European Countries 36

5.1.4 Japan 40 5.1.5 Canada 42 5.2 Drivers and Barriers 44 5.2.1 Drivers 44 5.2.2 Barriers 45 6 Deals and Strategic Consolidations 47 6.1 Major Deals 47 6.1.1 Octapharma Enters Into an Agreement with Pfizer 47 6.1.2 Grifols to Acquire Blood Transfusion Diagnostics Business from Novartis 47 6.1.3 Shin Poong Pharmaceutical and French Fractionation and Biotechnology Laboratory form a Koreabased Bio-pharmaceutical Joint Venture 47 6.1.4 Bain Capital Acquires 80% Stake in Plasma Resources UK 47 Browse Full Report With TOC @ http://www.radiantinsights.com/research/critical-caretherapeutics-in-major-developed-markets-to-2020-new-and-late-stage-four-factor-pccs-andrecombinant-products-to-drive-market 6.1.5 Biomat Acquires Three Plasma Donation Centers from Cangene 48 6.1.6 BioRx Enters into Co-Marketing Agreement with CSL Behring for Corifact 48 6.1.7 Baxter Announces Collaboration with Sanquin to Expand Capacity for Plasma Therapies 48 6.1.8 Shire Enters into Licensing Agreement with Sangamo BioSciences 48 6.1.9 Baxter Completes Acquisition of Rights to OBI-1 and Related Assets from Ipsen and Inspiration Biopharma 48 7 Critical Care Market to 2020 - Appendix 50 7.1 Abbreviations 50 7.2 References 51 7.3 Pipeline Products 54 7.4 Market Forecasts to 2020 55 7.4.1 Major Developed Markets 55

7.4.2 US 56 7.4.3 UK 58 7.4.4 France 59 7.4.5 Germany 61 7.4.6 Italy 62 7.4.7 Spain 64 7.4.8 Japan 65 7.4.9 Canada 67 7.5 Research Methodology 68 7.5.1 Coverage 68 7.5.2 Secondary Research 69 Browse Full Report With TOC @ http://www.radiantinsights.com/research/critical-caretherapeutics-in-major-developed-markets-to-2020-new-and-late-stage-four-factor-pccs-andrecombinant-products-to-drive-market 7.5.3 Primary Research 69 7.5.4 Therapeutic Landscape 69 7.5.5 Geographical Landscape 71 7.5.6 Pipeline Analysis 72 7.6 Expert Panel Validation 72 7.7 Contact Us 72 7.8 Disclaimer 72 List of Tables Table 1: Critical Care Market, Atryn, Development Timeline, 2007-2013 22 Table 2: Critical Care Market, Global, Pharmaceutical Pipeline, 2014 54 Table 3: Critical Care Market, Major Developed Markets, Market Forecast, 2013-2020 55 Table 4: Critical Care Market, Major Developed Markets, Albumin, Market Forecast, 2013-2020 55

Table 5: Critical Care Market, Major Developed Markets, Anti-Thrombin Concentrates, Market Forecast, 2013-2020 55 Table 6: Critical Care Market, Major Developed Markets, FXIII Concentrates, Market Forecast, 20132020 55 Table 7: Critical Care Market, Major Developed Markets, Fibrinogen Concentrates, Market Forecast, 2013-2020 56 Table 8: Critical Care Market, Major Developed Markets, Prothrombin Complex Concentrates, Market Forecast, 2013-2020 56 Table 9: Critical Care Market, US, Market Forecast, 2013-2020 56 Table 10: Critical Care Market, US, Albumin, Market Forecast, 2013-2020 56 Table 11: Critical Care Market, US, Anti-Thrombin Concentrates, Market Forecast, 2013-2020 57 Browse Full Report With TOC @ http://www.radiantinsights.com/research/critical-caretherapeutics-in-major-developed-markets-to-2020-new-and-late-stage-four-factor-pccs-andrecombinant-products-to-drive-market Table 12: Critical Care Market, US, FXIII Concentrates, Market Forecast, 2013-2020 57 Table 13: Critical Care Market, US, Fibrinogen Concentrates, Market Forecast, 2013-2020 57 Table 14: Critical Care Market, US, Prothrombin Complex Concentrates, Market Forecast, 2013-2020 57 Table 15: Critical Care Market, UK, Market Forecast, 2013-2020 58 Table 16: Critical Care Market, UK, Albumin, Market Forecast, 2013-2020 58 Table 17: Critical Care Market, UK, Anti-Thrombin Concentrates, Market Forecast, 2013-2020 58 Table 18: Critical Care Market, UK, FXIII Concentrates, Market Forecast, 2013-2020 58 Table 19: Critical Care Market, UK, Fibrinogen Concentrates, Market Forecast, 2013-2020 59 Table 20: Critical Care Market, UK, Market Forecast, Prothrombin Complex Concentrates, 2013-2020 59 Table 21: Critical Care Market, France, Market Forecast, 2013-2020 59 Table 22: Critical Care Market, France, Albumin, Market Forecast, 2013-2020 59 Table 23: Critical Care Market, France, Anti-Thrombin Concentrates, Market Forecast, 2013-2020 60 Table 24: Critical Care Market, France, FXIII Concentrates, Market Forecast, 2013-2020 60 Table 25: Critical Care Market, France, Fibrinogen Concentrates, Market Forecast, 2013-2020 60

Table 26: Critical Care Market, France, Prothrombin Complex Concentrates, Market Forecast, 2013-2020 60 Table 27: Critical Care Market, Germany, Market Forecast, 2013-2020 61 Table 28: Critical Care Market, Germany, Albumin, Market Forecast, 2013-2020 61 Table 29: Critical Care Market, Germany, Anti-Thrombin Concentrates, Market Forecast, 2013-2020 61 Table 30: Critical Care Market, Germany, FXIII Concentrates, Market Forecast, 2013-2020 61 Table 31: Critical Care Market, Germany, Fibrinogen Concentrates, Market Forecast, 2013-2020 62 Table 32: Critical Care Market, Germany, Prothrombin Complex Concentrates, Market Forecast, 20132020 62 Table 33: Critical Care Market, Italy, Market Forecast, 2013-2020 62 Table 34: Critical Care Market, Italy, Albumin, Market Forecast, 2013-2020 62 Table 35: Critical Care Market, Italy, Anti-Thrombin Concentrates, Market Forecast, 2013-2020 63 Table 36: Critical Care Market, Italy, FXIII Concentrates, Market Forecast, 2013-2020 63 Table 37: Critical Care Market, Italy, Fibrinogen Concentrates, Market Forecast, 2013-2020 63 Table 38: Critical Care Market, Italy, Prothrombin Complex Concentrates, Market Forecast, 2013-2020 63 Browse Full Report With TOC @ http://www.radiantinsights.com/research/critical-caretherapeutics-in-major-developed-markets-to-2020-new-and-late-stage-four-factor-pccs-andrecombinant-products-to-drive-market Table 39: Critical Care Market, Spain, Market Forecast, 2013-2020 64 Table 40: Critical Care Market, Spain, Albumin, Market Forecast, 2013-2020 64 Table 41: Critical Care Market, Spain, Anti-Thrombin Concentrates, Market Forecast, 2013-2020 64 Table 42: Critical Care Market, Spain, FXIII Concentrates, Market Forecast, 2013-2020 64 Table 43: Critical Care Market, Spain, Fibrinogen Concentrates, Market Forecast, 2013-2020 65 Table 44: Critical Care Market, Spain, Prothrombin Complex Concentrates, Market Forecast, 2013-2020 65 Table 45: Critical Care Market, Japan, Market Forecast, 2013-2020 65 Table 46: Critical Care Market, Japan, Albumin, Market Forecast, 2013-2020 65

Table 47: Critical Care Market, Japan, Anti-Thrombin Concentrates, Market Forecast, 2013-2020 66 Table 48: Critical Care Market, Japan, FXIII Concentrates, Market Forecast, 2013-2020 66 Table 49: Critical Care Market, Japan, Fibrinogen Concentrates, Market Forecast, 2013-2020 66 Table 50: Critical Care Market, Japan, Prothrombin Complex Concentrates, Market Forecast, 2013-2020 66 Table 51: Critical Care Market, Canada, Market Forecast, 2013-2020 67 Table 52: Critical Care Market, Canada, Albumin, Market Forecast, 2013-2020 67 Table 53: Critical Care Market, Canada, Anti-Thrombin Concentrates, Market Forecast, 2013-2020 67 Table 54: Critical Care Market, Canada, FXIII Concentrates, Market Forecast, 2013-2020 67 Table 55: Critical Care Market, Canada, Fibrinogen Concentrates, Market Forecast, 2013-2020 68 Table 56: Critical Care Market, Canada, Prothrombin Complex Concentrates, Market Forecast, 20132020 68 Browse Full Report With TOC @ http://www.radiantinsights.com/research/critical-caretherapeutics-in-major-developed-markets-to-2020-new-and-late-stage-four-factor-pccs-andrecombinant-products-to-drive-market List of Figures Figure 1: Critical Care Market, Global, Overall Pipeline Analysis (%), 2013 29 Figure 2: Critical Care Market, Major Developed Markets, Treatment Use Patterns, 2013-2020 32 Figure 3: Critical Care Market, Major Developed Markets, Revenue ($bn), 2013-2020 33 Figure 4: Critical Care Market, US, Treatment Use Patterns, 2013-2020 34 Figure 5: Critical Care Market, US, Annual Cost of Therapy and Revenue, 2013-2020 35 Figure 6: Critical Care Market, Top Five European Countries, Treatment Use Patterns, 2013 and 2020 37 Figure 7: Critical Care Market, Top Five European Countries, Annual Cost of Therapy ($), 2013-2020 38 Figure 8: Critical Care Market, Top Five European Countries, Revenue ($m), 2013-2020 39 Figure 9: Critical Care Market, Japan, Treatment Use Patterns, 2013-2020 40 Figure 10: Critical Care Market, Japan, Annual Cost of Therapy and Revenue, 2013-2020 41 Figure 11: Critical Care Market, Canada, Treatment Use Patterns, 2013-2020 42

Figure 12: Critical Care Market, Canada, Annual Cost of Therapy and Revenue, 2013-2020 43 Figure 13: GBI Research Market Forecasting Model 71 Browse Full Report With TOC @ http://www.radiantinsights.com/research/critical-caretherapeutics-in-major-developed-markets-to-2020-new-and-late-stage-four-factor-pccs-andrecombinant-products-to-drive-market About Radiant Insights Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.

For More Information, Visit Radiant Insights Contact: Michelle Thoras Corporate Sales Specialist, USA Radiant Insights, Inc Phone: 1-415-349-0054 Toll Free: 1-888-202-9519 Email: sales@radiantinsights.com Blog URL: http://chemicalmaterialsmarket.blogspot.in/